Cadila Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CADILA, and what generic and branded alternatives to CADILA drugs are available?
CADILA has forty-one approved drugs.
Summary for Cadila
US Patents: | 0 |
Tradenames: | 35 |
Ingredients: | 35 |
NDAs: | 41 |
Patent Litigation for Cadila: | See patent lawsuits for Cadila |
Drugs and US Patents for Cadila
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cadila | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 204189-001 | Aug 28, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Cadila Pharms Ltd | METRONIDAZOLE | metronidazole | TABLET;ORAL | 209794-001 | Dec 12, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-002 | Nov 21, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Cadila Pharms Ltd | OLANZAPINE | olanzapine | TABLET;ORAL | 210022-004 | Feb 24, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-001 | Nov 21, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Cadila Pharms Ltd | ACYCLOVIR | acyclovir | TABLET;ORAL | 202168-002 | Nov 15, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.